1. Histologically or cytologically confirmed stage IIIb-IVb NSCLC or postoperative recurrent NSCLC;

2. Positive EGFR test result, which can be determined by methods such as RT-PCR/FISH/IHC/NGS from hospital laboratories or testing institutions;

3. Patients aged ≥18 years;

4. Patients have clinically received Firmonertinib treatment, with recorded objective efficacy evaluation and adverse reactions;

5. Sign the Beijing Tiantan Hospital broad informed consent form.

Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis